All News

    Expanding Definition of Cancer Survivorship Highlights Need for New Standards

    April 14th 2025, 9:00pm

    Article

    Tara Sweeney, BSN, RN, OCN, CHPN discussed best care for the health and well-being of a person across all stages of their cancer survivorship.

    Radiation Therapy Advances Improve Quality of Life for GI Cancer

    April 14th 2025, 8:00pm

    Video

    Advancements in radiation therapy, including proton therapy and stereotactic radiation, reduce side effects and improve quality of life for GI cancer.

    FDA Approves Cabometyx, Another Treatment for Neuroendocrine Tumors

    April 14th 2025, 7:00pm

    Article

    The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

    Springtime Health After My Testicular Cancer Diagnosis

    April 14th 2025, 5:00pm

    Article

    Experiencing spring's renewal after a cancer diagnosis, I focus on health through checkups, diet and exercise, embracing change and well-being.

    AU-007 Combo Dosing Begins in Melanoma Phase 2 Trial With Opdivo

    April 14th 2025, 4:00pm

    Article

    AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity and manageable safety.

    Trial of SVV-001, Opdivo and Yervoy in Neuroendocrine Tumors Launching

    April 14th 2025, 3:00pm

    Article

    A phase 1 clinical trial is open for enrollment to patients with high-grade neuroendocrine tumors.

    Early Detection Critical for Testicular Cancer in Young Men

    April 14th 2025, 1:02pm

    Video

    April serves as Testicular Cancer Awareness Month, which is the most common type of cancer in men aged between 15 and 44 years old.

    Ziftomenib Submits New Drug Application to FDA for R/R NPM1-Mutant AML

    April 13th 2025, 6:00pm

    Article

    The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

    Phase 3 Trial Leads to FDA Approval of Cabometyx in Neuroendocrine Tumors

    April 13th 2025, 2:00pm

    Video

    Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors.

    NeuroSAFE May Increase Erectile Function After Prostate Cancer Surgery

    April 12th 2025, 6:00pm

    Article

    Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later.